BRAIN Biotech AG
BNN.DENext catalyst
INS-GSH
Parkinson Disease
Get an email about BNN.DE's next catalysts
Track BRAIN Biotech (BNN.DE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 0 past
INS-GSH Phase 2 Est. Readout (NOSE-PD)
Estimated primary completion for INS-GSH trial (NCT05266417) in Parkinson Disease. Topline data typically follows completion by weeks to months.
SourceMethylphenidate (MPH) Phase 2 Est. Readout (PRIME)
Estimated primary completion for Methylphenidate (MPH) trial (NCT07279740) in Alzheimer s Disease. Topline data typically follows completion by weeks to months.
SourceNabiximols Phase 2 Est. Readout (ARISTOCRAT)
Estimated primary completion for Nabiximols trial (NCT05629702) in Glioblastoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Celecoxib
Depressive Disorder, Major
Nerinetide (NA-1)
Acute Cerebral Ischemia
Escitalopram oxalate
Major Depressive Disorder
Progesterone
Alcohol Dependence
Inhaled isoflurane administered by Sedaconda ACD-S
Post-Intensive Care Syndrome
Levetiracetam
Parkinson Disease
Vismodegib
Intracranial Meningioma
Nitrous Oxide
Obsessive-Compulsive Disorder
TN-TC11G
Glioblastoma
Methylphenidate (MPH)
Alzheimer s Disease
Minocycline
Spinal Cord Injuries
Guanfacine
Schizotypal Personality Disorder
Mifepristone
Major Depressive Disorder
Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir
Leptomeningeal Metastasis of Breast Cancer
MMFS-202-302
Schizophrenia
Nabiximols
Glioblastoma
Sildenafil
Hypoactive Sexual Desire Disorder
Valacyclovir HCI
Schizophrenia
Sertraline
Neurodevelopmental Disorders
Ketamine
Bipolar Disorder
Capecitabine
Brainstem Glioma
Ganaxolone
PTSD
Roflumilast Oral Tablet
Cerebrovascular Disorders
CBD
Alzheimer Disease
Bezafibrate
Bipolar Disorder
adMSC
Cognitive Dysfunction
HSPPC-96
Brain and Central Nervous System Tumors
Palmitoylethanolamide (PEA)
Bipolar Depression
Probucol
Dementia of the Alzheimer Type
Neratinib
Glioblastoma
Levetiracetam (LEV)
Hippocampal Hyperactivation
Fluoxetine Hydrochloride
Stroke
QBS10072S
Glioblastoma
Treatment as Usual (TAU)
Bipolar Depression
Temozolomide Oral Product
Glioblastoma
CC-115
Glioblastoma
Rett-T
Rett Syndrome
Testosterone
Hypoactive Sexual Desire Disorder
Buspirone hydrochloride
Hypoactive Sexual Desire Disorder
INS-GSH
Parkinson Disease
0.5 mgTestosterone + Buspirone
Hypoactive Sexual Desire Disorder
Etidronate
Fahr Disease
Abemaciclib
Meningioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Celecoxib | Phase 3 | Depressive Disorder, Major | - | - |
Nerinetide (NA-1) | Phase 3 | Acute Cerebral Ischemia | - | - |
Escitalopram oxalate | Phase 3 | Major Depressive Disorder | - | - |
Progesterone | Phase 3 | Alcohol Dependence | - | - |
Inhaled isoflurane administered by Sedaconda ACD-S | Phase 3 | Post-Intensive Care Syndrome | - | - |
Levetiracetam | Phase 2 | Parkinson Disease | - | - |
Vismodegib | Phase 2 | Intracranial Meningioma | - | - |
Nitrous Oxide | Phase 2 | Obsessive-Compulsive Disorder | - | - |
TN-TC11G | Phase 2 | Glioblastoma | - | - |
Methylphenidate (MPH) | Phase 2 | Alzheimer s Disease | - | - |
Minocycline | Phase 2 | Spinal Cord Injuries | - | - |
Guanfacine | Phase 2 | Schizotypal Personality Disorder | - | - |
Mifepristone | Phase 2 | Major Depressive Disorder | - | - |
Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir | Phase 2 | Leptomeningeal Metastasis of Breast Cancer | - | - |
MMFS-202-302 | Phase 2 | Schizophrenia | - | - |
Nabiximols | Phase 2 | Glioblastoma | - | - |
Sildenafil | Phase 2 | Hypoactive Sexual Desire Disorder | - | - |
Valacyclovir HCI | Phase 2 | Schizophrenia | - | - |
Sertraline | Phase 2 | Neurodevelopmental Disorders | - | - |
Ketamine | Phase 2 | Bipolar Disorder | - | - |
Capecitabine | Phase 2 | Brainstem Glioma | - | - |
Ganaxolone | Phase 2 | PTSD | - | - |
Roflumilast Oral Tablet | Phase 2 | Cerebrovascular Disorders | - | - |
CBD | Phase 2 | Alzheimer Disease | - | - |
Bezafibrate | Phase 2 | Bipolar Disorder | - | - |
adMSC | Phase 2 | Cognitive Dysfunction | - | - |
HSPPC-96 | Phase 2 | Brain and Central Nervous System Tumors | - | - |
Palmitoylethanolamide (PEA) | Phase 2 | Bipolar Depression | - | - |
Probucol | Phase 2 | Dementia of the Alzheimer Type | - | - |
Neratinib | Phase 2 | Glioblastoma | - | - |
Levetiracetam (LEV) | Phase 2 | Hippocampal Hyperactivation | - | - |
Fluoxetine Hydrochloride | Phase 2 | Stroke | - | - |
QBS10072S | Phase 2 | Glioblastoma | - | - |
Treatment as Usual (TAU) | Phase 2 | Bipolar Depression | - | - |
Temozolomide Oral Product | Phase 2 | Glioblastoma | - | - |
CC-115 | Phase 2 | Glioblastoma | - | - |
Rett-T | Phase 2 | Rett Syndrome | - | - |
Testosterone | Phase 2 | Hypoactive Sexual Desire Disorder | - | - |
Buspirone hydrochloride | Phase 2 | Hypoactive Sexual Desire Disorder | - | - |
INS-GSH | Phase 2 | Parkinson Disease | - | - |
0.5 mgTestosterone + Buspirone | Phase 2 | Hypoactive Sexual Desire Disorder | - | - |
Etidronate | Phase 2 | Fahr Disease | - | - |
Abemaciclib | Phase 2 | Meningioma | - | - |
brain metastases detection
1 drug in this indication
ALK fusion lung adenocarcinoma with brain metastasis
1 drug in this indication
MRI contrast agent for brain metastasis detection
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in BRAIN Biotech AG's drug pipeline?→
CatalystAlert tracks 43 drug candidates in BRAIN Biotech AG's (BNN.DE) pipeline across Phase 3, Phase 2. Its lead program is Celecoxib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRAIN Biotech AG's next FDA catalyst?→
BRAIN Biotech AG's (BNN.DE) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BNN.DE biotech catalysts?→
Add BNN.DE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRAIN Biotech AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
